Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
about
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsMarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Tumor-Induced Local and Systemic Impact on Blood Vessel FunctionProfile of nintedanib in the treatment of solid tumors: the evidence to dateAnti-angiogenic alternatives to VEGF blockadeIntertwined regulation of angiogenesis and immunity by myeloid cellsCompensatory angiogenesis and tumor refractorinessApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsVascular endothelial growth factor-B in physiology and diseaseMouse models for studying angiogenesis and lymphangiogenesis in cancerThe emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitorsr84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionBiomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewG-Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1The metal-responsive transcription factor-1 protein is elevated in human tumorsPlacental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathyA role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability.Tumor angiogenesisVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging.Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).Role of placenta growth factor in cancer and inflammation.Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.Molecular regulation of tumor angiogenesis and perfusion via redox signaling.Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles.VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceVEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewTargeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.
P2860
Q24655930-158AF0C3-0523-427E-9F6A-BB6ED0A83494Q26738655-6BBA39D7-2A2B-444F-B719-9DD3010E2394Q26752752-E5D311C7-E8F5-4CEA-953A-0EDDA339F6DBQ26771958-5F744D93-5C49-4863-8FED-8D2A49872CF5Q26775134-F697A736-9337-4E72-82E1-AE2E701885B5Q26775947-4770DE5A-C112-4F35-83F4-B413C99E06B6Q26830418-1FCDF981-9BBC-4D8B-821C-78A42EF28FBCQ26851916-F3A6B986-00F7-4EB5-97D0-B0207BC3C0D1Q26852287-DA3B002C-1E7F-4E64-AA47-1DC359430FC0Q27003400-1674CE36-396F-49AA-BC4C-80CFE4D4ADC4Q27003898-85B58DE3-EDC8-4630-9383-6031E0EC9BDDQ27011540-9BE9C553-B06C-497D-BC60-08A693E12D04Q27321768-60117366-79DC-4AFA-BC53-2B744691593DQ27853358-204E87AE-3AD9-4D91-A786-7922669DE3F2Q28080338-BB1BAB23-22CD-4871-9666-A2985EA131DAQ28283859-E300879A-6703-46E2-8F2C-546BC53DAC6FQ28386210-63C0F4E5-464B-455F-8CE4-3019BE0E5685Q28565180-46F4DF91-8D7A-415B-9972-4EF9885B5A0AQ28566820-BBC4E44F-1824-4F56-8E03-E9B57C7ED690Q29614938-08A3779D-7FE6-49FF-B7DC-3D8179BECBFEQ30469815-96F8B28D-A9D5-4659-BC69-64B257055408Q30471456-C3F45BB0-B644-48E7-AFE2-4B3D904DA013Q30490563-AA8DA4D3-677C-4699-AEDE-17806992AA62Q30579125-D88ACD05-E759-4638-A88C-DC975052EC70Q31070048-6A267D2A-B044-4B18-B383-F8758AABF9ECQ33276211-86FB9849-30F1-48ED-B5F4-DD3A6AB34279Q33352793-34073E57-8ED8-4AB7-8796-C80DC30FDDBBQ33376945-4B717607-6341-4035-8923-2524E0D71DADQ33410375-D9640416-52D1-42D3-9E40-975648C857A9Q33424257-5E7BA1D8-DADC-4E82-89CE-0DE8AA84590EQ33504611-78CF0524-2D2E-43B6-89F1-265E0A1E828EQ33535171-7533CCBD-C5FA-4BC2-BA8A-736487B4B2C9Q33555154-BDA578ED-9CBB-424E-9C40-5C97E1A45560Q33572306-BF604C68-A282-448F-98A6-F7B2B50ED591Q33572498-46129A4E-626E-4BA8-A347-C2195FBDA5D6Q33615188-4210546A-4568-43C4-955E-53EDC90EAE66Q33627739-B1C09E43-CE34-42F4-B770-1193E6923874Q33640270-E8A8CE78-E068-4BEE-BF14-C8C31559F867Q33662162-A7145D60-A5EA-49D1-B496-F10CF562598AQ33680309-ABDCD87E-1F6F-4557-8248-D55D26216C01
P2860
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@ast
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en-gb
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@nl
type
label
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@ast
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en-gb
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@nl
prefLabel
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@ast
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en-gb
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@nl
P2093
P50
P3181
P1433
P1476
Anti-PlGF inhibits growth of V ...... hout affecting healthy vessels
@en
P2093
Bart Jonckx
Christian Fischer
Desire Collen
Emmanuel Chorianopoulos
Jean-Marie Stassen
Laurens Liesenborghs
Lucia Pattarini
Maria De Mol
Marta Koch
Mieke Dewerchin
P304
P3181
P356
10.1016/J.CELL.2007.08.038
P407
P577
2007-11-01T00:00:00Z